Currently, there are 45.48M common shares owned by the public and among those 39.42M shares have been available to trade.
The company’s stock has a 5-day price change of 6.86% and 12.16% over the past three months. IRD shares are trading -8.40% year to date (YTD), with the 12-month market performance down to -36.07% lower. It has a 12-month low price of $0.65 and touched a high of $2.18 over the same period. IRD has an average intraday trading volume of 211.67K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.94%, 17.38%, and -1.78% respectively.
Institutional ownership of Opus Genetics Inc (NASDAQ: IRD) shares accounts for 22.78% of the company’s 45.48M shares outstanding.
It has a market capitalization of $65.03M and a beta (3y monthly) value of -0.00. The earnings-per-share (ttm) stands at -$1.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.05% over the week and 3.69% over the month.
Earnings per share for the fiscal year are expected to increase by 60.62%, and 37.01% over the next financial year. EPS should grow at an annualized rate of 35.76% over the next five years, compared to 24.32% over the past 5-year period.
Looking at the support for the IRD, a number of firms have released research notes about the stock. Craig Hallum stated their Buy rating for the stock in a research note on April 11, 2025, with the firm’s price target at $6. H.C. Wainwright coverage for the Opus Genetics Inc (IRD) stock in a research note released on November 13, 2024 offered a Buy rating with a price target of $8.
